35 results
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
1 Apr 24
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
8:27am
from or related to geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
9:06am
business operations arising from or related to geo-political conflicts or a global pandemic and other factors, including general economic conditions
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
9:02am
arising from or related to geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
19 Mar 24
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
7:06am
; unforeseen circumstances or other disruptions to normal business operations arising from or related to geo-political conflicts or a global pandemic
8-K
EX-99.1
xbs d4kwsc5
20 Feb 24
Corporate Presentation February 2024
4:30pm
8-K
EX-99.1
0y9kewuwza04c00l4
20 Feb 24
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:05am
8-K
EX-99.1
j6t334z 2g8
4 Jan 24
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:11am
8-K
EX-99.1
4f0rkwtg wfrd
20 Oct 22
Other Events
7:05am
8-K
EX-99.1
ljec2k81
19 Aug 22
Other Events
7:05am
8-K/A
EX-99.1
341l4xwgu697z81
31 Mar 22
Asset Purchase Agreement
4:45pm
8-K
EX-99.1
djg64 aoeg
1 Mar 22
Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
7:06am